IMX-110 in Patients With Advanced Solid Tumors

Summary

Phase 1 is an open-label, multi-center dose escalation/dose expansion study designed to assess the safety, tolerability and pharmacokinetics (PK) for the recommended phase 2 dose (RP2D) of IMX-110. The RP2D will be evaluated in a further dose expansion Phase 2a study submitted.

Timeline

Start

2018-02-15

Primary completion

2023-10-31

Completion

2023-12-31

Drugs

Indications